NASDAQ:TLSA Tiziana Life Sciences Q2 2026 Earnings Results & Report $1.05 0.00 (0.00%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$1.08 +0.03 (+3.33%) As of 10/16/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tiziana Life Sciences reported Q2 2026 earnings on October 16, 2026. The company reported EPS of -$0.05. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateOctober 16, 2026TimeAfter Market Closes Tiziana Life Sciences EPS ResultsActual EPS-$0.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATiziana Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Tiziana Life Sciences Q2 2026 Earnings FAQ Did Tiziana Life Sciences beat earnings estimates for Q2 2026? Tiziana Life Sciences (NASDAQ:TLSA) reported earnings of -$0.05 per share for Q2 2026. The report was announced on Friday, October 16, 2026. Tiziana Life Sciences Earnings HeadlinesTiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 20264 hours ago | marketscreener.comMTiziana Life Sciences Doses Last Patient in Phase 2 Trial of Intranasal Foralumab in Alzheimer's DiseaseOctober 16 at 2:04 PM | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 17 at 1:00 AM | InvestorPlace (Ad)Tiziana Completes Enrollment And Dosing In Phase 2 Alzheimer's Study Of Intranasal ForalumabOctober 16 at 2:04 PM | rttnews.comTiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumabOctober 16 at 2:04 PM | finance.yahoo.comTiziana Life Sciences, Ltd. Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer?S DiseaseOctober 16 at 2:04 PM | marketscreener.comMSee More Tiziana Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tiziana Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tiziana Life Sciences and other key companies, straight to your email. Email Address About Tiziana Life SciencesTiziana Life Sciences (NASDAQ:TLSA). is a clinical-stage biotechnology company focused on developing therapies that regulate the immune system and address inflammatory and neurodegenerative diseases. The company’s research centers on treatments designed to modulate immune responses without broadly suppressing immune function. Tiziana’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells. The company is developing an intranasal formulation of foralumab for conditions associated with neuroinflammation, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease. Tiziana has also investigated the candidate in other inflammatory conditions. The company’s development activities involve clinical research and collaborations in the United States and other regions. Tiziana Life Sciences was founded by Dr. Kunwar Shailubhai, who has served as its chief executive officer and chief scientific officer and oversees the company’s scientific and development strategy.View Tiziana Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/12 - 10/16Bank of America Stock Sell-Off Looks Like a Buying OpportunityManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay SolidMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers? Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
